VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce the signing of a non-binding letter of intent ("LOI") with Awakn Life Sciences (NEO: AWKN)(OTCQB: AWKNF) ("Awakn"), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to better treat Addiction.
The Company will enter into an agreement with Awakn to be a distributor of its ketamine-assisted psychotherapy for Alcohol Use Disorder (AUD) protocol in the US and Canada. Awakn's protocol will be distributed through iSTRYM, MINDCURE's digital therapeutics platform.
MINDCURE released the minimum viable product (MVP) version of iSTRYM into partner clinics across North America in August and will begin full commercial deployment to all partner clinics in Q1 of 2022. The company forecasts 75 partner clinics in Canada and the US deploying iSTRYM upon commercialization. Further deployment anticipates 150 clinics across Canada, the US, the UK, and Europe by Q4 2022.
iSTRYM provides a digital distribution network of science-based protocols developed by MINDCURE's clinical partners, companies, academic institutions, and other healthcare providers directly to therapists. The Company is already partnering with ketamine-assisted psychotherapy clinics in nine states in the US and two provinces in Canada with plans to expand to the broader mental health market in 2022. The distribution component of iSTRYM unlocks another revenue line for MINDCURE, in addition to clinic and patient level revenues from the platform.
"Awakn's goal is to fully integrate evidence-backed psychedelic-assisted psychotherapy into mainstream healthcare to better treat addiction. We're currently building the UK and Europe's leading chain of medical psychedelic clinics with a focus on treating addiction and other mental health conditions," said Anthony Tennyson, CEO of Awakn Life Sciences. "We are extremely pleased that we now also have a partnership with MINDCURE to distribute our ketamine-assisted psychotherapy for Alcohol Use Disorder protocol through their iSTRYM platform in the US and Canada."
Awakn acquired the licensing rights from the University of Exeter for a ketamine-assisted psychotherapy treatment for AUD, which has been validated in a completed Phase II a/b trial. Awakn's license to use and deliver the 'Ketamine in the Reduction of Alcoholic Relapse' (KARE) psychotherapy treatment will be deployed in each of Awakn's clinics in the UK and Europe and will be led by a consultant psychiatrist. Awakn's Team includes world leading scientific, research and clinical experts in the treatment addiction, led by Professor David Nutt, who serves as Awakn's Chief Research Officer and Chair of both the Scientific Advisory Boards (Preclinical and Clinical). The KARE protocol will be distributed by MINDCURE in its digital therapeutic platform across its growing network of clinical partners in the US and Canada.
"Improving mental health is a global challenge and we're building iSTRYM to be an innovative global solution," said Kelsey Ramsden, President & CEO, MINDCURE. "This is our first of many overseas partnerships with industry leaders who are developing scientifically rigorous psychedelics protocols and drugs whereby our technology provides a natural distribution partner to support both patients and therapists."
Awakn Life Sciences ("Awakn") is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn's team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally. Learn more at awaknlifesciences.com
Mind Cure Health ("MINDCURE") is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.
On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Certain information presented in this news release may constitute "forward-looking information" within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "feel", "intend", "may", "plan", "predict", "project", "subject to", "will", "would", and similar terms and phrases.
Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE's business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE's business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE's products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; that trading on the OTCQX will attract additional investment and provide additional liquidity for shareholders
Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: iSTRYM distributing Awakn's ketamine-assisted psychotherapy for Alcohol Use Disorder protocol in the US and Canada. Although MINDCURE has attempted to identify important factors that could cause actual results, performance, or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.
Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Mind Cure Health Inc.